EQT Life Sciences Exits Tubulis Stake Through Gilead Sciences Deal Worth Up to $5 Billion EQT Life Sciences announces its exit from Tubulis, a German biotech firm, through a sale to Gilead Sciences for up to $5 billion, enhancing oncology innovation.

EQT Life Sciences Exits Tubulis Stake Through Gilead Sciences Deal Worth Up to $5 Billion #USA #Amsterdam #EQT_Life_Sciences #Gilead_Sciences #Tubulis

EQT Life Sciences Sells Minority Stake in Tubulis to Gilead Sciences for Major Deal EQT Life Sciences exits its minority stake in Tubulis through a significant sale to Gilead Sciences, highlighting innovative oncology platforms.

EQT Life Sciences Sells Minority Stake in Tubulis to Gilead Sciences for Major Deal #USA #Amsterdam #EQT_Life_Sciences #Gilead_Sciences #Tubulis

EQT Life Sciences Leads $39 Million Round for Aerska's RNA Therapeutics Innovation EQT Life Sciences has co-led a $39 million Series A financing round to enhance Aerska's technology delivering RNA medicines for neurological diseases, aiming to transform treatment options.

EQT Life Sciences Leads $39 Million Round for Aerska's RNA Therapeutics Innovation #USA #Amsterdam #EQT_Life_Sciences #RNA_Medicines #Aerska

EQT Life Sciences Invests $39 Million in Aerska's RNA Medicine Delivery Technology EQT Life Sciences co-leads a $39 million Series A funding for Aerska, which is developing advanced RNA medicines to treat neurological disorders.

EQT Life Sciences Invests $39 Million in Aerska's RNA Medicine Delivery Technology #Netherlands #Amsterdam #EQT_Life_Sciences #RNA_Medicines #Aerska

EQT Life Sciences Leads €51 Million Series B Funding in Exciva for Alzheimer's Therapy Advancement EQT Life Sciences co-leads a €51 million Series B in Exciva, aiming to advance its Alzheimer's therapy Deraphan into Phase 2 clinical trials.

EQT Life Sciences Leads €51 Million Series B Funding in Exciva for Alzheimer's Therapy Advancement #USA #Stockholm #EQT_Life_Sciences #Alzheimer's_therapy #Exciva

EQT Life Sciences Leads €51 Million Series B Funding in Exciva for Alzheimer's Therapy Progression EQT Life Sciences has co-led a €51 million Series B funding round in Exciva, aimed at advancing its Alzheimer's therapy, Deraphan, into Phase 2 clinical trials.

EQT Life Sciences Leads €51 Million Series B Funding in Exciva for Alzheimer's Therapy Progression #Sweden #Stockholm #EQT_Life_Sciences #Alzheimer's_therapy #Exciva

EQT Life Sciences Invests in Kinaset Therapeutics to Revolutionize Asthma Treatment EQT Life Sciences has announced a $103 million investment in Kinaset Therapeutics, aimed at advancing a novel inhaled therapy for asthma patients.

EQT Life Sciences Invests in Kinaset Therapeutics to Revolutionize Asthma Treatment #United_States #Boston #EQT_Life_Sciences #Kinaset_Therapeutics #Frevecitinib

EQT Life Sciences Completes Vivasure Medical Sale to Haemonetics EQT Life Sciences has exited Vivasure Medical through a transaction with Haemonetics, enhancing its closure technology offerings with PerQseal Elite.

EQT Life Sciences Completes Vivasure Medical Sale to Haemonetics #None #Haemonetics #EQT_Life_Sciences #Vivasure_Medical

EQT Life Sciences Takes Charge in $183 Million Series C Fundraising for Electra Therapeutics EQT Life Sciences co-leads a significant $183 million Series C round for Electra Therapeutics, aimed at advancing treatments for serious diseases.

EQT Life Sciences Takes Charge in $183 Million Series C Fundraising for Electra Therapeutics #United_States #Amsterdam #biotechnology #EQT_Life_Sciences #Electra_Therapeutics

EQT Life Sciences' ImCheck Therapeutics Acquired by Ipsen for Up to €1 Billion EQT Life Sciences' ImCheck Therapeutics is being acquired by Ipsen in a significant deal worth up to €1 billion, marking a major milestone for innovation in immuno-oncology.

EQT Life Sciences' ImCheck Therapeutics Acquired by Ipsen for Up to €1 Billion #France #EQT_Life_Sciences #Marseille #Ipsen #ImCheck_Therapeutics

Genmab's Historic Acquisition of Merus: A EUR 8.0 Billion Deal Genmab's acquisition of Merus for USD 8.0 billion marks a significant milestone in European biotech, spotlighting innovative cancer therapies.

Genmab's Historic Acquisition of Merus: A EUR 8.0 Billion Deal #None #EQT_Life_Sciences #Merus #Genmab

EQT Life Sciences Invests $44 Million in Cyted Health to Enhance US Market Reach EQT Life Sciences has led a $44 million Series B financing in Cyted Health, aiming to accelerate its US expansion and diagnostic innovations.

EQT Life Sciences Invests $44 Million in Cyted Health to Enhance US Market Reach #USA #Amsterdam #EQT_Life_Sciences #Cyted_Health #Series_B_Financing

EQT Life Sciences Secures $56 Million to Advance Neuros Medical's Pain Management Technology EQT Life Sciences leads a $56 million funding round for Neuros Medical to commercialize Altius®, an innovative treatment for post-amputation pain.

EQT Life Sciences Secures $56 Million to Advance Neuros Medical's Pain Management Technology #USA #Stockholm #EQT_Life_Sciences #Neuros_Medical #Altius

EQT Life Sciences Secures $135 Million Series B Funding for SpliceBio's Innovative Gene Therapy EQT Life Sciences alongside Sanofi Ventures has co-led a successful $135 million funding round to advance SpliceBio's groundbreaking gene therapy technology, targeting genetic diseases effectively.

EQT Life Sciences Secures $135 Million Series B Funding for SpliceBio's Innovative Gene Therapy #Sweden #Stockholm #gene_therapy #EQT_Life_Sciences #SpliceBio

EQT Life Sciences Raises $80 Million for Mosanna's Sleep Apnea Nasal Spray Development EQT Life Sciences has announced an $80 million investment in Mosanna Therapeutics to advance its nasal spray for sleep apnea treatment through clinical trials.

EQT Life Sciences Raises $80 Million for Mosanna's Sleep Apnea Nasal Spray Development #Sweden #Stockholm #Sleep_Apnea #EQT_Life_Sciences #Mosanna_Therapeutics

EQT Life Sciences Leads $75 Million Investment in Atalanta Therapeutics for Neurological Disease Solutions Atalanta Therapeutics has secured $75 million in Series B funding led by EQT Life Sciences to enhance RNAi therapies targeting epilepsy and Huntington's disease.

EQT Life Sciences Leads $75 Million Investment in Atalanta Therapeutics for Neurological Disease Solutions #USA #Boston #EQT_Life_Sciences #Atalanta_Therapeutics #RNA_Interference

EQT Life Sciences Boosts Noema Pharma's Series B Funding to CHF 130 Million EQT Life Sciences leads a Series B funding extension for Noema Pharma, increasing investment total to CHF 130 million, targeting CNS disorders.

EQT Life Sciences Boosts Noema Pharma's Series B Funding to CHF 130 Million #Switzerland #EQT_Life_Sciences #Noema_Pharma #CNS_disorders #Basel

EQT Life Sciences Drives Innovation in Maternal Health by Funding Nua Surgical's C-Section Device EQT Life Sciences has successfully led a €6.5 million funding round for Nua Surgical, focusing on improved C-section procedures with its innovative device, SteriCISION.

EQT Life Sciences Drives Innovation in Maternal Health by Funding Nua Surgical's C-Section Device #Ireland #Dublin #Nua_Surgical #SteriCISION #EQT_Life_Sciences